IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (DOCKET NO. API-02-13-US)

In the application of:)
) Examiner: Wu Cheng Winston Sher
Astsaturov, et al.)
) Art Unit: 1632
Application No.: 10/690,199)
Filed: 10/21/2003))
Title: VACCINES USING HIGH-DOSE	ý
CYTOKINES)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Submitted via EFS-Web

INFORMATION DISCLOSURE STATEMENT

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. Applicants do not believe any fees are due with this submission. If this is incorrect, the undersigned hereby authorizes the Commissioner to deduct any required fees from Deposit Account No. 500715. This Inormation Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application. In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

Non-Patent Documents

MITCHELL, et al. Increased Effectiveness of Interferon Alfa-2B Following Active Specific Immunotherapy for Melanoma. J. Clin. Oncol. 12: 402-411 (1994)

Respectfully Submitted,

Date: February 13, 2012 /Patrick J. Halloran/ Patrick J. Halloran

Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D. 3141 Muirfield Road Center Valley, PA 18034

Tel: 610-984-4751 Fax: 484-214-0164

Email: pat@pathalloran.com